Abstract
Gout causes extremely painful episodes of acute inflammatory arthritis, joint damage and chronic tophaceous disease. Comorbidities are common, even though their exact relationship with hyperuricemia and gout is currently uncertain. These comorbidities need to be taken into account in people who have them when treating their gout with pharmacological and nonpharmacological management, including lifestyle modification. Gout can be successfully managed in these people with consideration of the influence of medications used for gout and their impact on the components of the metabolic syndrome and on chronic renal impairment. The impact of medicines used to treat the comorbidities upon the management of acute gout, and on the requirement for reduction of uric acid to the target range of less than 6 mg/dl (0.36 mmol/l), is also important, along with drug interactions. Although there is a shortage of randomized controlled trials to guide treatment, attention to these factors, including the incorporation of patie...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
